13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001306923
Total reported value
$723.7M
$723.7M
51 檔
37.4%
According to the latest 13F quarterly dataset, Palo Alto Investors LP managed an equity portfolio of $723.7M at the end of Q1 2026, spanning 51 distinct U.S. exchange-listed positions.
Palo Alto Investors LP executed strategic sector rebalancing during Q1 2026, establishing 5 new positions while fully exiting 3 holdings and trimming 17 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | INSM | Insmed Inc | Stock-Healthcare | 10.39% | -4.29% | -15.16% | |
| 2 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 9.78% | +0.23% | +15.65% | |
| 3 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 9.60% | +0.76% | +1.96% | |
| 4 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 5.92% | -0.52% | -8.18% | |
| 5 | UTHR | United Therapeutics CORP | Stock-Healthcare | 5.70% | -1.01% | +7.95% | |
| 6 | ANAB | Anaptysbio Inc | Stock-Other | 5.41% | +0.22% | -7.52% | |
| 7 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 4.59% | +1.05% | +107.88% | |
| 8 | DYN | Dyne Therapeutics Inc | Stock-Other | 4.58% | +0.48% | +12.28% | |
| 9 | BIIB | Biogen Inc | Stock-Healthcare | 3.95% | +0.24% | -23.34% | |
| 10 | IRON | Disc Medicine Inc | Stock-Other | 3.93% | +0.28% | +26.54% | |
| 11 | IOVA | Iovance Biotherapeutics Inc | Stock-Other | 3.41% | -0.37% | -10.78% | |
| 12 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 3.09% | -0.48% | +8.87% | |
| 13 | ANNX | Annexon Inc | Stock-Other | 2.50% | -0.17% | +23.65% | |
| 14 | AM6 | Amicus Therapeutics Inc | Stock-Other | 2.46% | -2.46% | EXIT | |
| 15 | NVCR | NovoCure Limited | Stock-Healthcare | 2.13% | +0.55% | -1.43% | |
| 16 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.91% | +0.84% | +29.31% | |
| 17 | PRTA | Prothena Corporation plc | Stock-Other | 1.80% | -0.25% | -8.48% | |
| 18 | BCAX | Bicara Therapeutics Inc | Stock-Other | 1.67% | +0.59% | +84.34% | |
| 19 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.44% | +0.62% | — | |
| 20 | CDNA | Caredx Inc | Stock-Other | 1.41% | +0.68% | +11.22% | |
| 21 | ALKS | Alkermes plc | Stock-Healthcare | 1.31% | +0.45% | — | |
| 22 | CMPX | Compass Therapeutics Inc | Stock-Other | 1.23% | +0.53% | -40.20% | |
| 23 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 1.11% | -0.01% | +0.52% | |
| 24 | ALGN | Align Technology Inc | Stock-Healthcare | 1.09% | -0.36% | — | |
| 25 | CAPR | Capricor Therapeutics Inc | Stock-Other | 1.07% | -0.31% | +1.53% | |
| 26 | TVTX | Travere Therapeutics Inc | Stock-Other | 1.05% | +0.27% | +108.14% | |
| 27 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.95% | +0.36% | +17.60% | |
| 28 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 0.93% | +0.25% | +2.97% | |
| 29 | DNLI | Denali Therapeutics Inc | Stock-Other | 0.69% | -0.69% | EXIT | |
| 30 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.46% | -0.03% | -46.80% | |
| 31 | ORKA | Oruka Therapeutics Inc | Stock-Other | 0.45% | -0.01% | — | |
| 32 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.42% | -0.04% | +17.51% | |
| 33 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 0.41% | +0.01% | — | |
| 34 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 0.37% | +0.06% | — | |
| 35 | NUVB | Nuvation Bio Inc | Stock-Other | 0.33% | -0.07% | -5.43% | |
| 36 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.32% | +0.06% | — | |
| 37 | EHTH | Ehealth Inc | Stock-Other | 0.29% | +0.02% | -3.18% | |
| 38 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 0.29% | +0.01% | -3.93% | |
| 39 | BNTX | Biontech Se-adr | Stock-Other | 0.27% | -0.02% | — | |
| 40 | PYXS | Pyxis Oncology Inc | Stock-Other | 0.23% | +0.13% | -2.59% | |
| 41 | VSTM | Verastem Inc | Stock-Other | 0.20% | -0.04% | — | |
| 42 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.14% | -0.02% | -8.68% | |
| 43 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 0.14% | -0.01% | — | |
| 44 | HUM | Humana Inc | Stock-Healthcare | 0.11% | +0.11% | — | |
| 45 | CMPS | Compass Pathways PLC | Stock-Other | 0.10% | +0.13% | — | |
| 46 | XERS | Xeris Biopharma Holdings Inc | Stock-Other | 0.09% | +0.02% | — | |
| 47 | ABEO | Abeona Therapeutics Inc | Stock-Other | 0.07% | +0.02% | — | |
| 48 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 0.07% | -0.02% | — | |
| 49 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.07% | +0.05% | — | |
| 50 | ✓ | Proqr Therapeutics N.v. | Stock-Other | 0.05% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MIRM | Mirum Pharmaceuticals Inc | +2.9% | +107.88% | Add |
| 2 | UTHR | United Therapeutics CORP | +1.8% | +7.95% | Add |
| 3 | BCAX | Bicara Therapeutics Inc | +1% | +84.34% | Add |
| 4 | ANNX | Annexon Inc | +0.8% | +23.65% | Add |
| 5 | SNDX | Syndax Pharmaceuticals Inc | +0.8% | +8.87% | Add |
| 6 | ANAB | Anaptysbio Inc | +0.8% | -7.52% | Trim |
| 7 | IOVA | Iovance Biotherapeutics Inc | +0.7% | -10.78% | Trim |
| 8 | DYN | Dyne Therapeutics Inc | +0.6% | +12.28% | Add |
| 9 | ACAD | Acadia Pharmaceuticals Inc | +0.5% | +15.65% | Add |
| 10 | TVTX | Travere Therapeutics Inc | +0.5% | +108.14% | Add |
| 11 | RARE | Ultragenyx Pharmaceutical In | +0.4% | +29.31% | Add |
| 12 | IRON | Disc Medicine Inc | +0.4% | +26.54% | Add |
| 13 | ALKS | Alkermes plc | +0.4% | — | Unchanged |
| 14 | AGIO | Agios Pharmaceuticals Inc | +0.3% | +0.52% | Add |
| 15 | ACRS | Aclaris Therapeutics Inc | +0.3% | +2.97% | Add |
| 16 | ORKA | Oruka Therapeutics Inc | +0.2% | — | Unchanged |
| 17 | ALGN | Align Technology Inc | +0.2% | — | Unchanged |
| 18 | CAPR | Capricor Therapeutics Inc | +0.2% | +1.53% | Add |
| 19 | CDNA | Caredx Inc | +0.2% | +11.22% | Add |
| 20 | STOK | Stoke Therapeutics Inc | +0.1% | +17.51% | Add |
| 21 | PYXS | Pyxis Oncology Inc | +0.1% | -2.59% | Trim |
| 22 | PTCT | Ptc Therapeutics Inc | 0% | +1.96% | Add |
| 23 | PRTA | Prothena Corporation plc | 0% | -8.48% | Trim |
| 24 | TSHA | Taysha Gene Therapies Inc | 0% | +17.60% | Add |
| 25 | EW | Edwards Lifesciences CORP | 0% | — | Unchanged |
| 26 | BNTX | Biontech Se-adr | 0% | — | Unchanged |
| 27 | NBIX | Neurocrine Biosciences Inc | — | — | Unchanged |
| 28 | ✓ | Proqr Therapeutics N.v. | — | — | Unchanged |
| 29 | CRSP | CRISPR Therapeutics AG | 0% | -3.93% | Trim |
| 30 | CMPS | Compass Pathways PLC | 0% | — | Unchanged |
| 31 | URGN | UroGen Pharma Ltd. | 0% | — | Unchanged |
| 32 | ABEO | Abeona Therapeutics Inc | 0% | — | Unchanged |
| 33 | HUM | Humana Inc | 0% | — | Unchanged |
| 34 | INSP | Inspire Medical Systems Inc | 0% | — | Unchanged |
| 35 | BCYC | Bicycle Therapeutics Plc-adr | -0.1% | -8.68% | Trim |
| 36 | ALDX | Aldeyra Therapeutics Inc | -0.1% | -30.94% | Trim |
| 37 | XENE | Xenon Pharmaceuticals Inc | -0.1% | -46.80% | Trim |
| 38 | NVCR | NovoCure Limited | -0.2% | -1.43% | Trim |
| 39 | BMRN | Biomarin Pharmaceutical Inc | -0.3% | -8.18% | Trim |
| 40 | NUVB | Nuvation Bio Inc | -0.3% | -5.43% | Trim |
| 41 | BIIB | Biogen Inc | -0.6% | -23.34% | Trim |
| 42 | CMPX | Compass Therapeutics Inc | -0.7% | -40.20% | Trim |
| 43 | EHTH | Ehealth Inc | -0.7% | -3.18% | Trim |
| 44 | DNLI | Denali Therapeutics Inc | -0.8% | -63.42% | Trim |
| 45 | INSM | Insmed Inc | -1.5% | -15.16% | Trim |
| 46 | AM6 | Amicus Therapeutics Inc | -7.9% | -78.62% | Trim |
| 47 | GOSS | Gossamer Bio Inc | — | EXIT | Sold out |
| 48 | CLDX | Celldex Therapeutics Inc | — | NEW | New buy |
| 49 | CYTK | Cytokinetics Inc | — | NEW | New buy |
| 50 | VSTM | Verastem Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Palo Alto Investors LP reported a total U.S. public equity portfolio value of $723.7M across 51 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including INSM, ACAD, PTCT) accounted for 37.4% of total reported equity market value during Q1 2026.
Top New Position Initiated
CLDX
市值: $9.4M
Top Position Liquidated / Trimmed
GOSS
前期市值: $13.9M
During Q1 2026, Palo Alto Investors LP's top holdings by market value included INSM (10.4%)、ACAD (9.8%)、PTCT (9.6%). The largest single position, INSM, represented 10.4% of total portfolio value.
In Q1 2026, Palo Alto Investors LP made 42 total portfolio adjustments, initiating 5 new buys, adding to 17 positions, trimming 17 holdings, and fully liquidating 3 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.